skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
CDKI AT7519 (Code C64761)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: CDKI AT7519

Definition: An orally bioavailable small molecule with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some types of cancer cells.

NCI-GLOSS Definition: A substance being studied in the treatment of some types of cancer. AT7519M blocks enzymes needed for cells to divide. It is a type of cyclin-dependent kinase inhibitor.

Display Name: CDKI AT7519

Label: CDKI AT7519

NCI Thesaurus Code: C64761 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1879520  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
CDK inhibitor AT7519M
Cyclin-Dependent Kinase Inhibitor AT7519M

External Source Codes: 
CAS Registry Number 844442-38-2 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 513177
PDQ Open Trial Search ID 513177 (check for NCI PDQ open clinical trial info)
UMLS CUI C1879520

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C16H17Cl2N5O2
code C64761
Contributing_Source CTRP
Legacy_Concept_Name AT7519M
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom